A global pharmaceutical company headquartered in Japan, with USA operations, is actively seeking global collaboration and in-licensing opportunities within the early-stage ecosystem to strengthen their pipeline.
The company is seeking innovative therapies with highest focus on the following: CNS diseases, autoimmune diseases, and diabetes/kidney diseases. The company’s pipeline covers other indications as well and the company may review such opportunities on a case-by-case basis. The company is open to all stages of development, and those who have passed PoC are considered most ideal. The company has a strong interest in excellent technologies in biologics, including therapeutic antibodies, vaccines, and nucleic acid drugs, as well as cell-based phenotypic screening models of CNS or skeletal muscle diseases for new drug discovery.
Currently, the company’s main research focus can be broken down into 3 main branches: (1) nucleic acid medicine, (2) vaccines, and (3) macrocyclic compounds. In terms of their first interest, the company is highly interested in novel nucleic acid delivery systems targeted CNS and skeletal muscle, particularly those that could enable successful delivery from the gut. In terms of vaccines, the company is looking for innovative vaccine platforms to strengthen their current pipeline, which targets a broad range of infectious diseases. The last area of interest involves macrocyclic compounds with peptide modifications that could increase their cell permeability and therapeutic potential.
The company seeks to work with management teams with strong scientific expertise.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment